Which antidepressant should be avoided in adolescents due to a statistically increased risk of suicidality?

Which antidepressant should be avoided in adolescents due to a statistically increased risk of suicidality?

• A. Venlafaxine
• B. Fluoxetine
• C. Citalopram
• D. Sertraline

Answer: (A)

The main idea here is safety of antidepressants in adolescents, specifically the risk of suicidality. In youths, all antidepressants carry a warning about potential increases in suicidal thoughts or behaviors, so careful monitoring is essential. Among the options, venlafaxine has the strongest signal for a statistically increased risk of suicidality in adolescents based on pediatric trials and analyses. Because of this, it is generally avoided in this age group. Other antidepressants listed have different safety considerations or stronger pediatric data supporting their use. Fluoxetine is well supported for pediatric major depressive disorder and has a comparatively favorable safety and efficacy profile in youths, making it a preferred option. Citalopram carries concerns mainly about QT prolongation at higher doses rather than suicidality signaling. Sertraline is also used in pediatric populations for conditions like OCD and PTSD and is considered relatively safe, with suicidality risk not as prominently highlighted as with venlafaxine in adolescents. So, the reason venlafaxine is chosen is the observed higher risk of suicidality in adolescents, which tips the balance away from using it in this population.

The main idea here is safety of antidepressants in adolescents, specifically the risk of suicidality. In youths, all antidepressants carry a warning about potential increases in suicidal thoughts or behaviors, so careful monitoring is essential. Among the options, venlafaxine has the strongest signal for a statistically increased risk of suicidality in adolescents based on pediatric trials and analyses. Because of this, it is generally avoided in this age group.

Other antidepressants listed have different safety considerations or stronger pediatric data supporting their use. Fluoxetine is well supported for pediatric major depressive disorder and has a comparatively favorable safety and efficacy profile in youths, making it a preferred option. Citalopram carries concerns mainly about QT prolongation at higher doses rather than suicidality signaling. Sertraline is also used in pediatric populations for conditions like OCD and PTSD and is considered relatively safe, with suicidality risk not as prominently highlighted as with venlafaxine in adolescents.

So, the reason venlafaxine is chosen is the observed higher risk of suicidality in adolescents, which tips the balance away from using it in this population.